Sirtex Medical has today announced it has acquired the Hourglass embolization plug—a US Food and Drug Administration (FDA) 510(k)-cleared vascular plug indicated to obstruct or reduce the rate of blood flow in the peripheral vasculature in vessels 6–8mm in diameter.
Hourglass was previously introduced in the USA through a limited market release. According to a recent press release, Sirtex is completing the work needed to make the device available to physicians and will share availability details with customers.
“Dependable occlusion tools are central to treating a growing range of conditions with embolization. My experience with Hourglass was very positive, and I look forward to this device being available to physicians and their patients,” said Gary Siskin, professor and chair of radiology at Albany Medical Center in Albany, USA.
“Behind every embolization procedure is a patient who benefits from a less invasive path to treatment,” said Matt Schmidt, chief executive officer of Sirtex Medical. “Our investment in Hourglass is about making sure the physicians we work with have the right tools to deliver that care.”











